Codeine, ibuprofen, paracetamol
Sold as Mybulen, Gen-payne, Mybucod, Ibumol forte, Ibupain forte, Ibugesic forte, * gen-payne forte, Discpayne, Modupayne, Myprodol
S3Read from the PI-PIL document and verified
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Loading...
Loading Wikipedia summaryRegistration
- Applicants
- 4
- Registrations
- 13
- Schedule source
- SAHPRA documentation
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pharmacare limited û woodmeadCertificate held by Pharmacare limited1 of 5 cancelled | Mybulen, Mybucod, Ibumol forte | 10 mg/200 mg/350 mg, 200 mg/ 10 mg/ 250 mg | 300138, 360379, 360380, A380527, A390237 | S2 | PIPIL |
| Adcock ingram limitedCertificate held by Adcock lngram limited | Gen-payne, * gen-payne forte, Discpayne, Modupayne, Myprodol | capsules, 10 mg/200 mg/250 mg, 350 mg, 200 mg, 10 mg | 350046, 560960, 570731, 611506, T0244, Y0119 | S3 | PIPIL |
| Kiara Health (Pty) LtdCertificate held by Sandoz SA (Pty) Ltd1 | Ibupain forte | 200 mg | 370060 | S2 | PIPIL |
| Cipla Medpro (Pty) Ltd | Ibugesic forte | 10 mg, 200 mg, 250 mg | 370135 | S2 | PIPIL |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Mybulen EACH TABLET CONTAINS CODEINE PHOSPHATE 10 mg IBUPROFEN 200 mg PARACETAMOL 350 mg | Not listed | 30013830/2.8/0138 | Registered | Not determined | None |
| Gen-payne capsules EACH CAPSULE CONTAINS CODEINE PHOSPHATE 10,0 mg IBUPROFEN 200,0 mg PARACETAMOL 250,0 mg | Capsules | 35004635/2.8/0046 | Registered | Not determined | None |
| Mybucod EACH TABLET CONTAINS CODEINE PHOSPHATE 10,0 mg IBUPROFEN 200,0 mg PARACETAMOL 350,0 mg | 10 mg/200 mg/350 mgFilm-coated tablets | 36037936/2.8/0379Approved 24 October 2025 | Registered | S2 | PIPIL |
| Ibumol forte EACH TABLET CONTAINS CODEINE PHOSPHATE 10,0 mg IBUPROFEN 200,0 mg PARACETAMOL 350,0 mg | Not listed | 36038036/2.8/0380 | Cancelled | Not determined | None |
| Ibupain forte EACH CAPSULE CONTAINS CODEINE PHOSPHATE 10,0 mg IBUPROFEN 200,0 mg PARACETAMOL 250,0 mg | 200 mgCapsules | 37006037/2.8/0060Approved 29 September 2023 | Registered | S2 | PIPIL |
| Ibugesic forte EACH CAPSULE CONTAINS CODEINE PHOSPHATE 10,0 mg IBUPROFEN 200,0 mg PARACETAMOL 250,0 mg | 200 mg. 250 mg. 10 mgCapsules | 37013537/2.8/0135Approved 15 October 2024 | Registered | S2 | PIPIL |
| * gen-payne forte EACH TABLET CONTAINS: PARACETAMOL 350,0 mg, IBUPROFEN 200,0 mg, CODEINE PHOSPHATE 10,0 mg | Not listed | 56096056/2.8/0960 | Registered | Not determined | None |
| Discpayne EACH CAPSULE CONTAINS CODEINE PHOSPHATE 10,0 mg, IBUPROFEN 200,0 mg, PARACETAMOL 250,0 mg | Not listed | 57073157/2.8/0731 | Registered | Not determined | None |
| Modupayne EACH TABLET CONTAINS: PARACETAMOL 350,0 mg IBUPROFEN 200,0 mg CODEINE PHOSPHATE 10,0 mg | 350 mg, 200 mg, 10 mgFilm-coated tablet | 61150661/2.8/1506Approved 12 May 2026 | Registered | Not determined | PIPIL |
| Mybulen capsules EACH CAPSULE CONTAINS CODEINE PHOSPHATE 10,0 mg IBUPROFEN 200,0 mg PARACETAMOL 250,0 mg | 200 mg/ 10 mg/ 250 mgCapsules | A380527A38/2.8/0527Approved 23 December 2022 | Registered | S2 | PIPIL |
| Mybulen suspension EACH 10,0 ml SUSPENSION CONTAINS CODEINE PHOSPHATE 10,0 mg IBUPROFEN 200,0 mg PARACETAMOL 250,0 mg | 200 mg/ 10 mg/ 250 mgSuspension | A390237A39/2.8/0237Approved 18 November 2024 | Registered | S2 | PIPIL |
| Myprodol capsules EACH CAPSULE CONTAINS CODEINE PHOSPHATE 10 mg IBUPROFEN 2OO mg PARACETAMOL 250 mg | 10 mg/200 mg/250 mg.Hard capsules. | T0244T/2.8/244Approved 18 October 2024 | Registered | S3 | PIPIL |
| Myprodol suspension EACH 10 ml SUSPENSION CONTAINS CODEINE PHOSPHATE 10 mg IBUPROFEN 200 mg PARACETAMOL 250 mg | 10 mg/200 mg/250 mgSuspension | Y0119Y/2.8/119Approved 14 March 2025 | Registered | S3 | PIPIL |
Regulatory status
Where S3 sits on the scale
S0S1S2S3S4S5S6S7S8
Needs a doctor's prescription, dispensed by a pharmacist.
Schedule 3 medicines can only be sold on a prescription from an authorised prescriber, such as a doctor or dentist. A pharmacist dispenses the medicine once they have the written prescription, or a verbal instruction from a prescriber they know. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S3, read from the product's PI-PIL leaflet.
The Consolidated Schedules list this ingredient up to S6; the leaflet's S3 applies to this product.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Codeine phosphate, ibuprofen, paracetamol
S6: Codeine
- single component codeine preparations;
- oral solid preparations, in combination with one or more therapeutically active substances, in preparations not registered in terms of the Act, or when intended for export; (S2, S3)
- liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, in preparations not registered in terms of the Act, or when intended for export. (S2, S3)
Consolidated Schedules 06 July 2026, lines 10128 to 10136
S4: Ibuprofen
- Ibuprofen, when intended for the treatment of a haemodynamically significant patent ductus arterious in infants less than 34 weeks of gestational age;
- except when contained in preparations intended for application to the skin; containing 5 % m/m or less of ibuprofen; (S0, S1)
- except when contained in transdermal patches containing 200mg of ibuprofen per patch or less, and indicated for use by patients aged 16 years and older (S1)
- except when contained in oral medicinal preparations supplied in a solid dose form as divided doses contained in packs not exceeding 24 dosage units or divided doses and containing ibuprofen as the only active therapeutic substance, intended for the treatment of mild to moderate pain or fever of inflammatory origin or for the treatment of post-traumatic conditions in adults and children over 12 years of age where the recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children 12 years and older does not exceed 20 milligrams per kilogram of body weight; (S1)
- except when contained in oral medicinal preparations intended for human use only, in combination with one or more other active therapeutic substances and intended for the treatment of mild to moderate pain or fever of inflammatory origin for a maximum treatment period of 10 days where the recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children over the age of 1 year and up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight; (S2)
- except when contained in oral medicinal preparations, intended for human use only, as the only active therapeutic substance in oral liquid preparations in packs not exceeding 100 millilitres in volume or in oral solid preparations in packs exceeding 24 dosage units or divided doses, when intended for adults and children over the age of 1 year; for the treatment of mild to moderate pain of inflammatory origin for a maximum treatment period of 10 days, or for the treatment of fever of inflammatory origin or for the treatment of post-traumatic conditions where the recommended daily dose of ibuprofen for adults does not exceed 1,2 grams and for children over the age of 1 year and up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight; (S2)
- except for the emergency treatment of acute gout attacks for a maximum treatment period of 5 days; (S2)
- except when intended for veterinary use. (S3)
Consolidated Schedules 06 July 2026, lines 6660 to 6700
S3: Codeine
- oral solid preparations, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per dosage unit, when contained in products registered in terms of the Act, and not intended for export;
- liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, when contained in products registered in terms of the Act, and not intended for export;
- except oral solid preparations, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per dosage unit, with a maximum daily dose not exceeding 80 milligrams, and in packs containing sufficient dosage units for a maximum treatment period of 5 days and limited to one pack per customer, when contained in products registered in terms of the Act, and not intended for export; (S2)
- except liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, with a maximum daily dose not exceeding 80 milligrams, and with a pack size not exceeding 100 millilitres and limited to one pack per customer, when contained in products registered in terms of the Act, and not intended for export; (S2)
- except single component codeine preparations. (S6)
Consolidated Schedules 06 July 2026, lines 3350 to 3372
S3: Ibuprofen
- when contained in preparations intended for application to the skin, containing 5 % m/m or less of ibuprofen; (S0, S1)
- when contained in transdermal patches containing 200mg of ibuprofen per patch or less, and indicated for use by patients aged 16 years and older (S1)
- when contained in oral medicinal preparations supplied in a solid dose form as divided doses contained in packs not exceeding 24 dosage units or divided doses and containing ibuprofen as the only active therapeutic substance, intended for the treatment of mild to moderate pain or fever of inflammatory origin or for the treatment of post-traumatic conditions in adults and children over 12 years of age where the recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children 12 years and older does not exceed 20 milligrams per kilogram of body weight; (S1)
- when contained in oral medicinal preparations intended for human use only, in combination with one or more other active therapeutic substances and intended for the treatment of mild to moderate pain or fever of inflammatory origin for a maximum treatment period of 10 days where the recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children over the age of 1 year and up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight; (S2)
- when contained in oral medicinal preparations, intended for human use only, as the only active therapeutic substance in oral liquid preparations in packs not exceeding 100 millilitres in volume or in oral solid preparations in packs exceeding 24 dosage units or divided doses, when intended for adults and children over the age of 1 year; for the treatment of mild to moderate pain of inflammatory origin for a maximum treatment period of 10 days, or for the treatment of fever of inflammatory origin or for the treatment of post-traumatic conditions where the recommended daily dose of ibuprofen for adults does not exceed 1,2 grams and for children over the age of 1 year and up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight; (S2)
- for the emergency treatment of acute gout attacks for a maximum treatment period of 5 days; (S2)
- when intended for the treatment of haemodynamically significant patent ductus arteriosus in infants less than 34 weeks of gestational age. (S4)
Consolidated Schedules 06 July 2026, lines 3734 to 3772
S3: Paracetamol
- when intended for injection.
Consolidated Schedules 06 July 2026, line 4093
S2: Codeine
- oral solid preparations, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per dosage unit, with a maximum daily dose not exceeding 80 milligrams, and in packs containing sufficient dosage units for a maximum treatment period of 5 days, and limited to one pack per customer, when contained in products registered in terms of the Act, and not intended for export;
- liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing not more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit, with a maximum daily dose not exceeding 80 milligrams, and with a pack size not exceeding 100 millilitres, when contained in products registered in terms of the Act, and not intended for export;
- except oral solid preparations, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per dosage unit; (S3)
- except liquid oral preparations and mixtures, in combination with one or more therapeutically active substances, containing more than 10 milligrams of codeine (calculated as base) per 5 millilitre dosage unit; (S3)
- except single component codeine preparations. (S6)
Consolidated Schedules 06 July 2026, lines 1758 to 1778
S2: Ibuprofen
- when contained in oral medicinal preparations, intended for human use only in combination with one or more other active therapeutic substances and intended for the treatment of mild to moderate pain or fever of inflammatory origin for a maximum treatment period of 10 days where the recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children over the age of 1 year and up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight. (S3)
- when contained in oral medicinal preparations, intended for human use only as the only active therapeutic substance in oral liquid preparations in packs not exceeding 100 millilitres in volume or in oral solid preparations in packs exceeding 24 dosage units or divided doses, when intended for adults and children over the age of 1 year; for the treatment of mild to moderate pain of inflammatory origin for a maximum treatment period of 10 days, or for the treatment of fever of inflammatory origin or for the treatment of post-traumatic conditions where the recommended daily dose of ibuprofen for adults does not exceed 1,2 grams and for children over the age of 1 year and up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight; (S1, S3)
- for the emergency treatment of acute gout attacks for a maximum treatment period of 5 days; (S3)
- except when contained in preparations intended for application to the skin, containing 5 % m/m or less of ibuprofen; (S0, S1)
- except when contained in transdermal patches containing 200mg of ibuprofen per patch or less, and indicated for use by patients aged 16 years and older (S1);
- except when contained in oral medicinal preparations supplied in a solid dose form as divided doses contained in packs not exceeding 24 dosage units or divided doses and containing ibuprofen as the only active therapeutic substance, intended for the treatment of mild to moderate pain or fever of inflammatory origin or for the treatment of post-traumatic conditions in adults and children over 12 years of age where the recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children 12 years and older does not exceed 20 milligrams per kilogram of body weight; (S1)
- except when intended for the treatment of haemodynamically significant patent ductus arteriosus in infants less than 34 weeks of gestational age; (S4)
- except when intended for veterinary use. (S3)
Consolidated Schedules 06 July 2026, lines 2126 to 2165
S2: Paracetamol
- when contained in rectal suppositories, or
- when contained in modified release formulations. (S0, S1, S3)
Consolidated Schedules 06 July 2026, lines 2496 to 2500
S1: Ibuprofen
- when contained in preparations intended for application to the skin, containing 5 % m/m or less of ibuprofen, and presented in a pack size exceeding 50 grams; (S0)
- when contained in transdermal patches containing 200mg of ibuprofen per patch or less, and indicated for use by patients aged 16 years and older;
- when contained in oral medicinal preparations, intended for human use only, supplied in a solid dose form as divided doses contained in packs not exceeding 24 dosage units or divided doses and containing ibuprofen as the only active therapeutic substance, intended for the treatment of mild to moderate pain or fever of inflammatory origin or for the treatment of post-traumatic conditions in adults and children over 12 years of age where the recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children 12 years and older does not exceed 20 milligrams per kilogram of body weight. (S2, S3).
- except when intended for the treatment of haemodynamically significant patent ductus arteriosus in infants less than 34 weeks of gestational age; (S4)
- except when intended for veterinary use. (S3)
Consolidated Schedules 06 July 2026, lines 533 to 548
S1: Paracetamol
- immediate release tablets or capsules each containing 500 milligrams or less of paracetamol, or in individually wrapped powders or in sachets containing 1 000 milligrams or less of paracetamol, subject to - (i) a maximum of 12,5 grams of paracetamol per primary pack, and (ii) in the case of tablets or capsules, presented in blister strip packaging or in containers with child-resistant closures; and (iii) labelled with the following boxed warning, placed prominently on at least the main panel of the immediate container label and outer label (carton): “CONTAINS PARACETAMOL - READ THE PACKAGE INSERT”; (S0)
- in liquid or syrup dosage form containing 120 milligrams or less of paracetamol per 5 millilitres or in paediatric drops containing 120 milligrams or less of paracetamol per 1,2 millilitres, subject to - (i) a maximum of 100 millilitres per primary pack in the case of the liquid or syrup dosage form containing 120 milligrams or less of paracetamol per 5 millilitres; (ii) a maximum of 20 millilitres per primary pack in the case of the paediatric drops; (iii) labelled with the following boxed warning, placed prominently on at least the main panel of the immediate container label and outer label (carton): “CONTAINS PARACETAMOL - READ THE PACKAGE INSERT”; (S0)
- when contained in rectal suppositories. (S2)
- when contained in modified release formulations. (S2)
- when intended for injection. (S3)
Consolidated Schedules 06 July 2026, lines 958 to 997
Pharmacological class: Analgesic combinations. (class 2.8)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
Schedule verified from official documents
Schedule Verification
Mybucod, Pharmacare limited û woodmead is scheduled S2 in its official SAHPRA documents, read with 90% confidence.
Professional information (PI)For healthcare professionalsMybucod, Pharmacare limited û woodmeadPatient information leaflet (PIL)For patients and carersMybucod, Pharmacare limited û woodmead
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.
Research articles
Loading...
Loading PubMed articles